Wednesday, December 7, 2022 | Back issues
Courthouse News Service Courthouse News Service

GlaxoSmithKline

PHILADELPHIA - Blue Cross Blue Shield claims GlaxoSmithKline keeps its $1.3 billion annual monopoly on Wellbutrin SR (bupropion) through "fraudulent statements to patent examiners" and "filing baseless patent infringement actions" against generic manufacturers.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...